Skip to content
Tenfell
Awarded contract
Published 09 Aug 2019

NHS Framework Agreement for Branded Medicines - National

NHS England · London

Key facts

Awarded
30 Apr 2019
Contract starts
30 Apr 2019
Contract ends
30 Apr 2021
Procedure
Open procedure (above threshold)
Buyer type
Central government

Awarded to 50 suppliers

SupplierValue
Takeda UK Limited—
Almirall Ltd—
Aventis Pharma Ltd Trading As Sanofi—
Consilient Health Ltd—
Crescent Pharma Limited—
Focus Pharmaceuticals Ltd—
GlaxoSmithKline—
Janssen-Cilag Ltd—
Pfizer Ltd—
Teva UK Ltd—
Bayer plc—
Beaver Visitec International Sales Ltd—
Abbvie Ltd—
Aguettant Ltd—
B. Braun Medical Limited—
Ennogen Healthcare Ltd—
Kent Pharmaceuticals Ltd—
Napp Pharmaceuticals—
Rosemont Pharmaceuticals Ltd—
Sandoz Ltd—
Selective Supplies Ltd—
Typharm Ltd—
Accord-UK Ltd—
AstraZeneca—
Eli Lilly & Company Ltd—
Gedeon Richter UK Ltd—
Gilead Sciences Limited—
Ipsen—
Neon Healthcare Ltd—
Novartis Pharmaceuticals UK Ltd—
Novo Nordisk—
Roche Products Ltd—
UCB Pharma Ltd—
Zentiva Pharma UK Ltd—
Drugsrus Ltd—
medac Pharma LLP—
Thea Pharmaceuticals Limited—
Tillomed Laboratories ltd—
FLYNN PHARMA LTD—
Glenmark Pharmaceuticals Europe Ltd—
Intrapharm Laboratories Ltd—
Kyowa Kirin Limited—
Aspire Pharma Ltd—
Dr Falk Pharma UK Ltd—
Ferring Pharmaceuticals Limited—
Macarthys Laboratories t/a Martindale Pharma—
Morningside Pharmaceuticals Limited—
Norgine Pharmaceuticals Limited—
Lupin Healthcare UK Ltd—
Mercury Pharmaceuticals Limited—

Description

NHS Framework Agreement for Branded Medicines - National Contract Period: 1 May 2019 to 30 April 2021 (with an option to extend for a period or periods of up 24 months) Tender Reference: CM/PHR/16/5518

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.